Vertex EVP sells 1,846 shares in 10b5-1 trade

Vertex Pharmaceuticals executive Amit Sachdev reported share sales and related tax withholding transactions.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Amit Sachdev reported share sales and related tax withholding transactions. On February 25, 2026, he completed an open-market sale of 1,846 shares of common stock at $486.35 per share, leaving him with 55,570 directly held shares.

On February 24, 2026, he disposed of 1,518 shares of common stock at $485.11 per share to cover tax obligations by delivering shares. He also reported indirect holdings of 882 shares in a 401(k) plan and 9,301 shares held in a trust. The filing notes that the sale was made under a company-approved Rule 10b5-1 trading plan entered into on November 18, 2025.

Insider Trade Summary

Net Seller: 1,846 shares

Net Sell 4 txns

Insider Sachdev Amit

Role EVP Chief Patient & Ext Af Off

Sold 1,846 shs ($898K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,846	$486.35	$898K
Exercise Price or Tax Liability	Common Stock	1,518	$485.11	$736K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 55,570 shares (Direct); Common Stock — 882 shares (Indirect, 401(k)); Common Stock — 9,301 shares (Indirect, Held in Trust)

Footnotes (1)

1. F1. Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vertex (VRTX) executive Amit Sachdev report?

Amit Sachdev reported selling 1,846 shares of Vertex common stock at $486.35 per share in an open-market trade. The transaction occurred on February 25, 2026 under a pre-established Rule 10b5-1 trading plan approved by the company.

Were any Vertex (VRTX) shares disposed of for tax withholding by Amit Sachdev?

Yes. On February 24, 2026, Amit Sachdev disposed of 1,518 Vertex common shares at $485.11 per share to satisfy tax obligations by delivering shares. This tax-withholding disposition reduced his directly held balance but did not represent an open-market sale.

How many Vertex (VRTX) shares does Amit Sachdev hold after these transactions?

After the reported transactions, Amit Sachdev directly holds 55,570 Vertex common shares. He also reports indirect beneficial ownership of 882 shares through a 401(k) plan and 9,301 shares held in a trust, reflecting both direct and indirect positions.

Was Amit Sachdev’s Vertex (VRTX) share sale made under a Rule 10b5-1 plan?

The filing states the sale was made pursuant to a company-approved Rule 10b5-1 trading plan. This plan was entered into on November 18, 2025 and allows pre-scheduled transactions, providing a structured framework for selling shares over time.

What is the nature of the indirect Vertex (VRTX) holdings reported by Amit Sachdev?

The filing lists two types of indirect holdings for Amit Sachdev. It reports 882 Vertex common shares in a 401(k) account and 9,301 shares held in a trust, indicating retirement-plan and trust-based ownership in addition to his directly held shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 06:50 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sachdev Amit

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Chief Patient & Ext Af Off

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		F		1,518	D	$485.11	57,416	D
Common Stock	02/25/2026		S(1)		1,846	D	$486.35	55,570	D
Common Stock								882	I	401(k)
Common Stock								9,301	I	Held in Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.